Insurers should be barred from setting premiums using genetic tests

CDC and HHS leadership, research integrity, bioethics, regulatory appointments, e-cigarette regulation, and global health funding.

Medicaid, Medicare, ACA, NHS, insurance coverage, prior authorization, healthcare workforce, and access disparities.

Medicare Part B/D, Medicare Advantage, IRA drug negotiations, 340B, most-favored-nation pricing, and federal drug pricing policy.

Medicaid cuts, funding freezes, state waivers, directed payments, CHIP, and state-level healthcare access policies.

Medical debt, out-of-pocket costs, voter concerns, racial disparities, rural access, and international healthcare access.

Nurse shortages, telehealth expansion, NHS workforce, hospital consolidation, and psychiatric care access.

ACA enrollment, premiums, marketplace cancellations, Essential Plan, uninsured rate, and insurance regulation.

Adherence to laws and safety standards.

Ethical issues in medicine and biomedical research: gene editing, reproductive technology, end-of-life care, organ markets, performance enhancement, and dual-use research.

CRISPR gene editing, epigenetic programming, behavioral genetics, commercial surrogacy, and human reproductive technology ethics.

Application of genetics in clinical care.

Study of genes and genetic information.